Year: 2021
Type: review
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Defense, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Merck, Gilead Sciences, AbbVie, Arrowhead Pharmaceuticals, National Institutes of Health, Allergan, Gilead UK and Ireland Corporate Contributions, National Institute on Alcohol Abuse and Alcoholism, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Center for Advancing Translational Sciences
Awards: A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?, DETECTION AND MODELS OF TOXICANT EXPOSURE, Non-invasive screening of diabetics for advanced fibrosis due to NAFLD, Novel IL-23 inhibitor for the treatment of alcohol associated liver disease, Ancillary Studies of NAFLD and NASH in HIV infected Adults, ABBREVIATED MAGNETIC RESONANCE IMAGING AND BIOMARKER-BASED DETECTION OF EARLY LIVER CANCER, QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD, G6827194995, UC San Diego Clinical and Translational Research Institute, GENETIC EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASE, San Diego Digestive Diseases Research Center, Clinical Research on Nonalcoholic Fatty Liver Disease, San Diego Cirrhosis Clinical Research Network
OpenAlex ID: W3135797835